During that same time span, the number of people with no insurance coverage for another GLP-1 receptor agonist, Zepbound, increased by 14%, which meant that another 4.9 million or so more people ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

A person can get Zepbound through Medicare Part D or Part C plans with drug coverage to treat this condition ... you in making personal decisions about insurance, but it is not intended to ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the ...